Characterization of human papillomavirus antibodies in individuals with head and neck cancer

Abstract

Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized.

Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n=25).

Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n=6] and 100% [95% CI: 60-100%, n=4] compared to 0% (n=2) and 0% (n=13) for non-OPC cases.

Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.

Keywords: HPV antibodies; HPV seropositivity; HPV16; HPV16 E6; Human papillomavirus 16; Non-OPC; Non-oropharyngeal cancer; OPC; Oropharyngeal cancer.

Conflict of interest statement

Conflict of Interest

The authors have no conflicts of interest to declare.

Copyright © 2016 Elsevier Ltd. All rights reserved.

Figures

Figure 1

Cumulative all-cause mortality for non-OPC HPV16 E6 seronegative cases (blue), non-OPC HPV16 E6 seropositive cases (red), OPC HPV16 E6 seronegative cases (green) and OPC HPV16 E6 seropositive cases (yellow).